12:00 AM
 | 
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Amitiza lubiprostone: Phase III started

Sucampo and Takeda began a double-blind, placebo-controlled, international Phase III trial to evaluate 12 or 24 µg oral lubiprostone twice daily for 12 weeks in >500 patients ages 6-17 years with functional constipation. The companies' Phase III program for lubiprostone in pediatric functional constipation will comprise 2...

Read the full 214 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >